Differential expression of somatostatin receptor subtypes in hepatocellular carcinomas
Somatostatin analogues inhibit cell proliferation by stimulation of distinct somatostatin receptor (SSTR) subtypes. In recent years, these compounds have been introduced into the therapy of advanced hepatocellular carcinoma (HCC). The efficacy of this treatment is under debate due to the controversi...
Gespeichert in:
| Veröffentlicht in: | Journal of hepatology 2004-07, Vol.41 (1), p.112-118 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 118 |
|---|---|
| container_issue | 1 |
| container_start_page | 112 |
| container_title | Journal of hepatology |
| container_volume | 41 |
| creator | Bläker, Michael Schmitz, Michael Gocht, Andreas Burghardt, Sylvia Schulz, Martina Bröring, Dieter C. Pace, Andrea Greten, Heiner de Weerth, Andreas |
| description | Somatostatin analogues inhibit cell proliferation by stimulation of distinct somatostatin receptor (SSTR) subtypes. In recent years, these compounds have been introduced into the therapy of advanced hepatocellular carcinoma (HCC). The efficacy of this treatment is under debate due to the controversial results of clinical trials. Despite the widespread clinical use of somatostatin analogues in HCC, little is known about the expression of each of the five SSTRs in these tumors.
We analyzed the expression of SSTR subtypes in 56 HCCs by immunohistochemistry using subtype-specific antibodies. Six of the samples were also investigated by RT-PCR using subtype-specific oligonucleotide primers.
HCCs display differential, individual expression patterns as well as variable expression levels for SSTRs. The overall expression rate of SSTR1, SSTR2, SSTR3, SSTR4, and SSTR5 is 46, 41, 64, 0, and 75%, respectively. No significant correlation was observed between SSTR expression and tumor stage, differentiation, histological tumor type, or underlying liver disease.
Individual patterns and levels of SSTR expression might determine the response to treatment with somatostatin analogues in HCC. Selective treatment of these tumors based on the analysis of SSTR subtype expression might lead to an increase in response rates. |
| doi_str_mv | 10.1016/j.jhep.2004.03.018 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_66694751</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S016882780400131X</els_id><sourcerecordid>66694751</sourcerecordid><originalsourceid>FETCH-LOGICAL-c382t-1b761471b594e9842ad565c83246d711c25e1fd551d5f8934556a297cb2be19d3</originalsourceid><addsrcrecordid>eNp9kMFq3DAQhkVpaLZpX6CH4Etzs6uRJdmGXEqSpoVALm2vQpbHVIvXcjRySd6-2uxCesppYPj-mZ-PsU_AK-Cgv2yr7R9cKsG5rHhdcWjfsA1ozkuuJbxlmwy1ZSua9pS9J9pyzmveyXfsFJSQWoDesN_Xfhwx4py8nQp8XCIS-TAXYSwo7GwKlGzycxHR4ZJCLGjt09OCVORlfp8Jh9O0TjYWzkbn55yiD-xktBPhx-M8Y7--3fy8-l7e3d_-uPp6V7q6FamEvtEgG-hVJ7FrpbCD0sq1da43NABOKIRxUAoGNbZdLZXSVnSN60WP0A31Gbs43F1ieFiRktl52vexM4aVjNa6k42CDIoD6GIgijiaJfqdjU8GuNnbNFuzt2n2Ng2vTbaZQ-fH62u_w-ElctSXgc9HwJKz0xjt7Dz9x3VK8ufvlwcOs4u_HqMh53F2OPjsNZkh-Nd6_AN5-pPR</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>66694751</pqid></control><display><type>article</type><title>Differential expression of somatostatin receptor subtypes in hepatocellular carcinomas</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Bläker, Michael ; Schmitz, Michael ; Gocht, Andreas ; Burghardt, Sylvia ; Schulz, Martina ; Bröring, Dieter C. ; Pace, Andrea ; Greten, Heiner ; de Weerth, Andreas</creator><creatorcontrib>Bläker, Michael ; Schmitz, Michael ; Gocht, Andreas ; Burghardt, Sylvia ; Schulz, Martina ; Bröring, Dieter C. ; Pace, Andrea ; Greten, Heiner ; de Weerth, Andreas</creatorcontrib><description>Somatostatin analogues inhibit cell proliferation by stimulation of distinct somatostatin receptor (SSTR) subtypes. In recent years, these compounds have been introduced into the therapy of advanced hepatocellular carcinoma (HCC). The efficacy of this treatment is under debate due to the controversial results of clinical trials. Despite the widespread clinical use of somatostatin analogues in HCC, little is known about the expression of each of the five SSTRs in these tumors.
We analyzed the expression of SSTR subtypes in 56 HCCs by immunohistochemistry using subtype-specific antibodies. Six of the samples were also investigated by RT-PCR using subtype-specific oligonucleotide primers.
HCCs display differential, individual expression patterns as well as variable expression levels for SSTRs. The overall expression rate of SSTR1, SSTR2, SSTR3, SSTR4, and SSTR5 is 46, 41, 64, 0, and 75%, respectively. No significant correlation was observed between SSTR expression and tumor stage, differentiation, histological tumor type, or underlying liver disease.
Individual patterns and levels of SSTR expression might determine the response to treatment with somatostatin analogues in HCC. Selective treatment of these tumors based on the analysis of SSTR subtype expression might lead to an increase in response rates.</description><identifier>ISSN: 0168-8278</identifier><identifier>EISSN: 1600-0641</identifier><identifier>DOI: 10.1016/j.jhep.2004.03.018</identifier><identifier>PMID: 15246216</identifier><identifier>CODEN: JOHEEC</identifier><language>eng</language><publisher>Oxford: Elsevier B.V</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; Biological and medical sciences ; Carcinoma, Hepatocellular - genetics ; Carcinoma, Hepatocellular - pathology ; Carcinoma, Hepatocellular - physiopathology ; Child ; Gastroenterology. Liver. Pancreas. Abdomen ; Gene Expression Regulation, Neoplastic ; Hepatocellular carcinoma ; Humans ; Immunohistochemistry ; Infant ; Liver - pathology ; Liver - physiology ; Liver Neoplasms - genetics ; Liver Neoplasms - pathology ; Liver Neoplasms - physiopathology ; Liver. Biliary tract. Portal circulation. Exocrine pancreas ; Medical sciences ; Membrane Proteins ; Middle Aged ; Receptors, Somatostatin - genetics ; Receptors, Somatostatin - metabolism ; Reverse Transcriptase Polymerase Chain Reaction ; Somatostatin ; Somatostatin receptors ; Tumors</subject><ispartof>Journal of hepatology, 2004-07, Vol.41 (1), p.112-118</ispartof><rights>2004 European Association for the Study of the Liver</rights><rights>2004 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c382t-1b761471b594e9842ad565c83246d711c25e1fd551d5f8934556a297cb2be19d3</citedby><cites>FETCH-LOGICAL-c382t-1b761471b594e9842ad565c83246d711c25e1fd551d5f8934556a297cb2be19d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jhep.2004.03.018$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15954051$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15246216$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bläker, Michael</creatorcontrib><creatorcontrib>Schmitz, Michael</creatorcontrib><creatorcontrib>Gocht, Andreas</creatorcontrib><creatorcontrib>Burghardt, Sylvia</creatorcontrib><creatorcontrib>Schulz, Martina</creatorcontrib><creatorcontrib>Bröring, Dieter C.</creatorcontrib><creatorcontrib>Pace, Andrea</creatorcontrib><creatorcontrib>Greten, Heiner</creatorcontrib><creatorcontrib>de Weerth, Andreas</creatorcontrib><title>Differential expression of somatostatin receptor subtypes in hepatocellular carcinomas</title><title>Journal of hepatology</title><addtitle>J Hepatol</addtitle><description>Somatostatin analogues inhibit cell proliferation by stimulation of distinct somatostatin receptor (SSTR) subtypes. In recent years, these compounds have been introduced into the therapy of advanced hepatocellular carcinoma (HCC). The efficacy of this treatment is under debate due to the controversial results of clinical trials. Despite the widespread clinical use of somatostatin analogues in HCC, little is known about the expression of each of the five SSTRs in these tumors.
We analyzed the expression of SSTR subtypes in 56 HCCs by immunohistochemistry using subtype-specific antibodies. Six of the samples were also investigated by RT-PCR using subtype-specific oligonucleotide primers.
HCCs display differential, individual expression patterns as well as variable expression levels for SSTRs. The overall expression rate of SSTR1, SSTR2, SSTR3, SSTR4, and SSTR5 is 46, 41, 64, 0, and 75%, respectively. No significant correlation was observed between SSTR expression and tumor stage, differentiation, histological tumor type, or underlying liver disease.
Individual patterns and levels of SSTR expression might determine the response to treatment with somatostatin analogues in HCC. Selective treatment of these tumors based on the analysis of SSTR subtype expression might lead to an increase in response rates.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biological and medical sciences</subject><subject>Carcinoma, Hepatocellular - genetics</subject><subject>Carcinoma, Hepatocellular - pathology</subject><subject>Carcinoma, Hepatocellular - physiopathology</subject><subject>Child</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Gene Expression Regulation, Neoplastic</subject><subject>Hepatocellular carcinoma</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Infant</subject><subject>Liver - pathology</subject><subject>Liver - physiology</subject><subject>Liver Neoplasms - genetics</subject><subject>Liver Neoplasms - pathology</subject><subject>Liver Neoplasms - physiopathology</subject><subject>Liver. Biliary tract. Portal circulation. Exocrine pancreas</subject><subject>Medical sciences</subject><subject>Membrane Proteins</subject><subject>Middle Aged</subject><subject>Receptors, Somatostatin - genetics</subject><subject>Receptors, Somatostatin - metabolism</subject><subject>Reverse Transcriptase Polymerase Chain Reaction</subject><subject>Somatostatin</subject><subject>Somatostatin receptors</subject><subject>Tumors</subject><issn>0168-8278</issn><issn>1600-0641</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMFq3DAQhkVpaLZpX6CH4Etzs6uRJdmGXEqSpoVALm2vQpbHVIvXcjRySd6-2uxCesppYPj-mZ-PsU_AK-Cgv2yr7R9cKsG5rHhdcWjfsA1ozkuuJbxlmwy1ZSua9pS9J9pyzmveyXfsFJSQWoDesN_Xfhwx4py8nQp8XCIS-TAXYSwo7GwKlGzycxHR4ZJCLGjt09OCVORlfp8Jh9O0TjYWzkbn55yiD-xktBPhx-M8Y7--3fy8-l7e3d_-uPp6V7q6FamEvtEgG-hVJ7FrpbCD0sq1da43NABOKIRxUAoGNbZdLZXSVnSN60WP0A31Gbs43F1ieFiRktl52vexM4aVjNa6k42CDIoD6GIgijiaJfqdjU8GuNnbNFuzt2n2Ng2vTbaZQ-fH62u_w-ElctSXgc9HwJKz0xjt7Dz9x3VK8ufvlwcOs4u_HqMh53F2OPjsNZkh-Nd6_AN5-pPR</recordid><startdate>20040701</startdate><enddate>20040701</enddate><creator>Bläker, Michael</creator><creator>Schmitz, Michael</creator><creator>Gocht, Andreas</creator><creator>Burghardt, Sylvia</creator><creator>Schulz, Martina</creator><creator>Bröring, Dieter C.</creator><creator>Pace, Andrea</creator><creator>Greten, Heiner</creator><creator>de Weerth, Andreas</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20040701</creationdate><title>Differential expression of somatostatin receptor subtypes in hepatocellular carcinomas</title><author>Bläker, Michael ; Schmitz, Michael ; Gocht, Andreas ; Burghardt, Sylvia ; Schulz, Martina ; Bröring, Dieter C. ; Pace, Andrea ; Greten, Heiner ; de Weerth, Andreas</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c382t-1b761471b594e9842ad565c83246d711c25e1fd551d5f8934556a297cb2be19d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biological and medical sciences</topic><topic>Carcinoma, Hepatocellular - genetics</topic><topic>Carcinoma, Hepatocellular - pathology</topic><topic>Carcinoma, Hepatocellular - physiopathology</topic><topic>Child</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Gene Expression Regulation, Neoplastic</topic><topic>Hepatocellular carcinoma</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Infant</topic><topic>Liver - pathology</topic><topic>Liver - physiology</topic><topic>Liver Neoplasms - genetics</topic><topic>Liver Neoplasms - pathology</topic><topic>Liver Neoplasms - physiopathology</topic><topic>Liver. Biliary tract. Portal circulation. Exocrine pancreas</topic><topic>Medical sciences</topic><topic>Membrane Proteins</topic><topic>Middle Aged</topic><topic>Receptors, Somatostatin - genetics</topic><topic>Receptors, Somatostatin - metabolism</topic><topic>Reverse Transcriptase Polymerase Chain Reaction</topic><topic>Somatostatin</topic><topic>Somatostatin receptors</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bläker, Michael</creatorcontrib><creatorcontrib>Schmitz, Michael</creatorcontrib><creatorcontrib>Gocht, Andreas</creatorcontrib><creatorcontrib>Burghardt, Sylvia</creatorcontrib><creatorcontrib>Schulz, Martina</creatorcontrib><creatorcontrib>Bröring, Dieter C.</creatorcontrib><creatorcontrib>Pace, Andrea</creatorcontrib><creatorcontrib>Greten, Heiner</creatorcontrib><creatorcontrib>de Weerth, Andreas</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of hepatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bläker, Michael</au><au>Schmitz, Michael</au><au>Gocht, Andreas</au><au>Burghardt, Sylvia</au><au>Schulz, Martina</au><au>Bröring, Dieter C.</au><au>Pace, Andrea</au><au>Greten, Heiner</au><au>de Weerth, Andreas</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Differential expression of somatostatin receptor subtypes in hepatocellular carcinomas</atitle><jtitle>Journal of hepatology</jtitle><addtitle>J Hepatol</addtitle><date>2004-07-01</date><risdate>2004</risdate><volume>41</volume><issue>1</issue><spage>112</spage><epage>118</epage><pages>112-118</pages><issn>0168-8278</issn><eissn>1600-0641</eissn><coden>JOHEEC</coden><abstract>Somatostatin analogues inhibit cell proliferation by stimulation of distinct somatostatin receptor (SSTR) subtypes. In recent years, these compounds have been introduced into the therapy of advanced hepatocellular carcinoma (HCC). The efficacy of this treatment is under debate due to the controversial results of clinical trials. Despite the widespread clinical use of somatostatin analogues in HCC, little is known about the expression of each of the five SSTRs in these tumors.
We analyzed the expression of SSTR subtypes in 56 HCCs by immunohistochemistry using subtype-specific antibodies. Six of the samples were also investigated by RT-PCR using subtype-specific oligonucleotide primers.
HCCs display differential, individual expression patterns as well as variable expression levels for SSTRs. The overall expression rate of SSTR1, SSTR2, SSTR3, SSTR4, and SSTR5 is 46, 41, 64, 0, and 75%, respectively. No significant correlation was observed between SSTR expression and tumor stage, differentiation, histological tumor type, or underlying liver disease.
Individual patterns and levels of SSTR expression might determine the response to treatment with somatostatin analogues in HCC. Selective treatment of these tumors based on the analysis of SSTR subtype expression might lead to an increase in response rates.</abstract><cop>Oxford</cop><pub>Elsevier B.V</pub><pmid>15246216</pmid><doi>10.1016/j.jhep.2004.03.018</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0168-8278 |
| ispartof | Journal of hepatology, 2004-07, Vol.41 (1), p.112-118 |
| issn | 0168-8278 1600-0641 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_66694751 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Adolescent Adult Aged Aged, 80 and over Biological and medical sciences Carcinoma, Hepatocellular - genetics Carcinoma, Hepatocellular - pathology Carcinoma, Hepatocellular - physiopathology Child Gastroenterology. Liver. Pancreas. Abdomen Gene Expression Regulation, Neoplastic Hepatocellular carcinoma Humans Immunohistochemistry Infant Liver - pathology Liver - physiology Liver Neoplasms - genetics Liver Neoplasms - pathology Liver Neoplasms - physiopathology Liver. Biliary tract. Portal circulation. Exocrine pancreas Medical sciences Membrane Proteins Middle Aged Receptors, Somatostatin - genetics Receptors, Somatostatin - metabolism Reverse Transcriptase Polymerase Chain Reaction Somatostatin Somatostatin receptors Tumors |
| title | Differential expression of somatostatin receptor subtypes in hepatocellular carcinomas |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T18%3A40%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Differential%20expression%20of%20somatostatin%20receptor%20subtypes%20in%20hepatocellular%20carcinomas&rft.jtitle=Journal%20of%20hepatology&rft.au=Bl%C3%A4ker,%20Michael&rft.date=2004-07-01&rft.volume=41&rft.issue=1&rft.spage=112&rft.epage=118&rft.pages=112-118&rft.issn=0168-8278&rft.eissn=1600-0641&rft.coden=JOHEEC&rft_id=info:doi/10.1016/j.jhep.2004.03.018&rft_dat=%3Cproquest_cross%3E66694751%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=66694751&rft_id=info:pmid/15246216&rft_els_id=S016882780400131X&rfr_iscdi=true |